Baseline visit (n =83) | Follow up at 6 months (n =70) | P-value | |
---|---|---|---|
Age at inclusion, years† | 51.8 (11.7) | n.a. | n.a. |
Female, n (%) | 22 (26.2) | n.a. | n.a. |
Body mass index, kg/m2‡ | 27.2 (18.5 to 46.8) | n.a. | n.a. |
Disease duration, years‡ | 7.5 (0 to 44.7) | n.a. | n.a. |
Patients with a new diagnosis¥, n (%) | 4 (4.8) | n.a. | n.a. |
Axial involvement, n (%) | 11 (13.3) | n.a. | n.a. |
Smokers, n (%) | n.a. | n.a. | |
Current | 21 (25.3) | ||
Previous | 32 (38.6) | ||
PASDAS‡ | 5.9 (1.5) | 5.2 (1.5) | <0.001 |
DAPSA‡ | 11.5 (0.1 to 70.2) | 7.2 (0.1 to 73.5) | 0.016 |
CPDAI‡ | 3.0 (0 to 9.0) | 2.0 (0 to 11.0) | 0.019 |
CRP, mg/L ‡ | 2.2 (0 to 49.5) | 2.4 (0.2 to 35.0) | n.s. |
ESR, mm/1st hour‡ | 9.5 (1 to 74) | 10 (2 to 51) | n.s. |
TJ, 68-joint count‡ | 4 (0 to 59) | 1 (0 to 53) | 0.012 |
SJ, 66-joint count‡ | 1 (0 to 15) | 0 (0 to 17) | 0.011 |
PGA, mm† | 31.2 (22.7) | 21.3 (23.5) | 0.073 |
Ptpain, mm† | 30.5 (24.5) | 20.7 (21.0) | <0.001 |
EGA, mm† | 22.0 (19.1) | 11.5 (14.6) | 0.009 |
HAQ† | 0.7 (0.8) | 0.6 (0.7) | <0.001 |
BASDAI‡ | 4.7 (0.9 to 5.5) | 3.0 (0 to 6.0) | n.s. |
ASQol‡ | 2.0 (0 to 11.0) | 4.0 (0 to 8.0) | n.s. |
Leeds enthesitis score‡ | 0 (0 to 4) | 0 (0 to 2) | n.s. |
Dactylitis score‡ | 0 (0 to 10) | 0 (0 to 4) | n.s. |
PASI‡ | 1.0 (0 to 23.2) | 0.4 (0 to 36.3) | n.s. |
DLQI‡ | 1.0 (0 to 20.0) | 1.0 (0 to 18.0) | n.s. |
DMARDs, n (%) | n.s. | ||
MTX | 33 (39.8) | 30 (42.9) | |
LFN | 11 (13.3) | 12 (17.1) | |
MTX + LFN | 3 (3.6) | 3 (4.3) | |
SSZ | 2 (2.4) | 2 (2.9) | |
Anti-TNFα | 31 (37.3) | 30 (42.9) | |
Corticosteroids, n (%) | 6 (7.2) | 4 (5.7) | n.s. |
NSAIDs, n (%) | n.s. | ||
On demand | 56 (67.5) | 57 (81.4) | |
Regular intake | 10 (12.0) | 8 (11.4) |